Drug intelligence / Profile preview

BM-R13

Development stage: Preclinical
Lead developer: Shenzhen Beimei Pharmaceutical

Overview

BM-R13 is a preclinical drug candidate being developed by Beimei Pharmaceutical (also known as Bainei Pharmaceutical) for the treatment of acute poisoning. As of early 2024, the drug remains in the early stages of development, and specific details regarding its pharmacological profile, including its molecular target, modality (e.g., small molecule or biologic), and the specific type of toxin it is intended to counteract, have not been publicly disclosed. The project is part of Beimei Pharmaceutical's specialized pipeline focused on emergency medicine and toxicology treatments.

Beyond the preview

Go deeper on BM-R13.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BM-R13.

Explore the full profile